

Coverage of any medical intervention discussed in a Medica medical policy is subject to the limitations and exclusions outlined in the member's benefit certificate or summary plan description (SPD) and to applicable state and/or federal laws.

**Spinal Cord and Dorsal Root Ganglion (DRG)
Stimulation For Treatment of Pain**

MP9430

Covered Service:

Yes

**Prior Authorization
Required:**

Yes, for both spinal cord stimulation trial and permanent implantation, including reoperation. Prior authorization is not required for removal without intended reoperation/implantation.

**Additional
Information:**

None

Medica Medical Policy:

Spinal Cord Stimulation

- 1.0 Trial spinal cord stimulation (SCS) **require** prior authorization through the Health Services Division and is considered medically necessary when **ALL** of the following criteria are met:
 - 1.1 Spinal cord stimulator system has received final FDA approval. Examples of FDA approved devices include, but are not limited to:
 - 1.1.1 Eon® Neurostimulation Systems (St. Jude Medical)
 - 1.1.2 Precision™ Spinal Cord Stimulation Systems, now marketed as Precision Plus SCS System (Boston Scientific)
 - 1.1.3 Protégé System (St. Jude Medical)
 - 1.1.4 Restore™ Systems (Medtronic)
 - 1.1.5 Senza Spinal Cord Stimulation System (Nevro Corp.); **AND**
 - 1.2 Member has a diagnosis of **one of the following** chronic neuropathic pain conditions of the trunk or limbs:
 - 1.2.1 Complex regional pain syndrome (also known as reflex sympathetic dystrophy, algoneurodystrophy/algodystrophy, causalgia syndrome); **OR**
 - 1.2.2 Failed back surgery syndrome (FBSS); **OR**
 - 1.2.3 Moderate to severe diabetic peripheral neuropathy, when **all** of the following criteria have been met:
 - 1.2.3.1 Pain scale intensity rating of 50% or higher using a standard pain relief inventory assessment tool (e.g., Visual Analog Scale, Numeric Rating Scale, Verbal Rating Scale); **AND**
 - 1.2.3.2 Neuropathic pain refractory to a minimum of twelve months of conservative therapy, including **all** of the following therapies:

Coverage of any medical intervention discussed in a Medica medical policy is subject to the limitations and exclusions outlined in the member's benefit certificate or summary plan description (SPD) and to applicable state and/or federal laws.

- 1.2.3.2.1. Non-steroidal anti-inflammatory drug (NSAIDS); **AND**
- 1.2.3.2.2. Antidepressant; **AND**
- 1.2.3.2.3. Anticonvulsant; **AND**
- 1.3 Documentation of **ALL** of the following:
 - 1.3.1 Intractable pain for a minimum of twelve months duration; **AND**
 - 1.3.2 Failure of standard therapy (e.g., conservative management, standard surgical intervention) or unsuitability of standard therapies; **AND**
 - 1.3.3 Comprehensive physical examination, including pain evaluation; **AND**
- 1.4 Psychiatric/psychological evaluation has been conducted, and **ALL** of the following apply:
 - 1.4.1 Evaluation has been completed within the past 12 months; **AND**
 - 1.4.2 Continued optimal management of any previously diagnosed (greater than twelve months) mental or neurobehavioral condition(s); **AND**
- 1.5 **None of the following** contraindications are present:
 - 1.5.1 Implanted cardiac pacemaker or defibrillator
 - 1.5.2 Coagulation disorder (e.g., coagulopathy, severe thrombocytopenia)
 - 1.5.3 Current or chronic infection
 - 1.5.4 Malignancy-derived pain
 - 1.5.5 Vascular claudication.
- 2.0 Permanent spinal cord stimulation implantation **requires** prior authorization through the Health Services Division and is considered medically necessary when **ALL** of the following criteria are met:
 - 2.1 Medical necessity criteria is consistent with (1.1) to (1.5) above; **AND**
 - 2.2 Member has completed a trial using either percutaneous leads or surgically implanted leads with documentation of **ALL** of the following:
 - 2.2.1 Trial duration of a minimum of three days; **AND**
 - 2.2.2 Greater than or equal to 50% reduction in pain using a standard pain relief inventory assessment tool (e.g., Visual Analog Scale, Numeric Rating Scale, Verbal Rating Scale).
- 3.0 Spinal cord stimulation **reoperation requires** prior authorization through the Health Services Division and is considered medically necessary when **ONE** of the following are met:
 - 3.1 Development of fibrosis surrounding the electrode tip
 - 3.2 Electrode misalignment or migration has occurred
 - 3.3 Infection necessitating removal of the stimulation system

Coverage of any medical intervention discussed in a Medica medical policy is subject to the limitations and exclusions outlined in the member's benefit certificate or summary plan description (SPD) and to applicable state and/or federal laws.

- 3.4 Spinal cord stimulator and/or the battery are no longer operational
- 4.0 Dorsal root ganglion stimulation for the treatment of pain is considered **experimental and investigational**, and therefore not medically necessary.
- 5.0 Spinal cord stimulation of the dorsal column for the treatment of intractable pain is considered **experimental and investigational**, and therefore not medically necessary, for any indications not addressed in this policy, including but not limited to:
 - 5.1 Angina pectoris/myocardial ischemia
 - 5.2 Arachnoiditis
 - 5.3 Cancer associated pain
 - 5.4 Chronic visceral abdominal pain
 - 5.5 Cluster/migraine headache
 - 5.6 Intercostal neuralgia
 - 5.7 Lower limb ischemia (chronic/critical)
 - 5.8 Non-diabetic peripheral neuropathy
 - 5.9 Phantom limb syndrome
 - 5.10 Post herpetic neuralgia
 - 5.11 Post-cervical spine surgery
 - 5.12 Spinal cord injury

	Committee/Source	Date(s)
Document Created:	Medical Policy Committee/Health Services Division	February 20, 2019
Revised:	Medical Policy Committee/Health Services Division	August 21, 2019
	Medical Policy Committee/Health Services Division	August 19, 2020
	Medical Policy Committee/Health Services Division	April 21, 2021
	Medical Policy Committee/Health Services Division	June 16, 2021
	Medical Policy Committee/Health Services Division	January 18, 2023
	Medical Policy Committee/Health Services Division	September 20, 2023
Reviewed:	Medical Policy Committee/Health Services Division	August 21, 2019
	Medical Policy Committee/Health Services Division	August 19, 2020
	Medical Policy Committee/Health Services Division	April 21, 2021
	Medical Policy Committee/Health Services Division	June 16, 2021
	Medical Policy Committee/Health Services Division	January 18, 2023
	Medical Policy Committee/Health Services Division	September 20, 2023

Published: 10/01/2023
Effective: 01/01/2024